Today, as a result of a rise in antibiotic resistance, infectious diseases represent a major challenge for public health and are listed as the No.1 priority by the World Health Organization. In this context, Vivexia specialized in evaluating the efficacy of anti-infective drugs in living humanized models.
For more than 10 years, we have been providing a wide range of in vivo and in vitro models that can be applied to the development of anti-infective treatments for use by public health laboratories, healthcare facilities, TPE, SME and large companies within the pharmaceutics industry with which we enjoy a close collaboration.
Vivexia’s mission is to offer evaluation models that are as predictive as possible of the potential of your therapeutic innovations. In addition, we have developed and validated more than thirty pathological infection models.
Vivexia has developed an expertise in microbiology that allows us to offer a whole range of support services for the in vitro evaluation (susceptibility / resistance) of your anti-infective molecules, whatever their nature.
Vivexia will present its data on multidrug resistant Acinetobacter baumannii pneumonia models (posters 2132 & 2240) at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which will be held from 15th to 18th April in Copenhagen! https://www.escmid.org/dates_events/eccmid